Literature DB >> 27252845

Socioeconomic status affects pulmonary hypertension disease severity at time of first evaluation.

Arunabh Talwar1, Sonu Sahni1, Ankoor Talwar2, Nina Kohn3, James R Klinger4.   

Abstract

A low socioeconomic status (SES) has been linked to disproportionate access to health care in many diseases, leading to worse disease severity at initial presentation. There is a paucity of these data in the pulmonary hypertension (PHTN) population. We studied the association of SES, as measured by zip code-based median annual household income, with World Health Organization functional class (WHO-FC) at time of first evaluation in PHTN patients. All patients evaluated at our center with a right heart catheterization revealing a mean pulmonary artery pressure of ≥25 mmHg within 12 months of initial evaluation were considered for the study. Demographics, WHO-FC, and zip codes were obtained from retrospective chart analysis. The 2010 US census was used to obtain zip code-based annual median income. The income groups were divided into quartiles. Patients were categorized by their WHO-FC and zip code-derived median income. Similar analyses were conducted for pulmonary arterial hypertension (PAH) patients. Survival was estimated with the Kaplan-Meier method. Data were analyzed in SAS, and P < 0.05 was considered significant. There were 228 PHTN patients (70 [30.7%] male, 158 [69.3%] female). As median income decreased, the FC at presentation increased, signifying higher disease severity (Spearman correlation: r = -0.161, P < 0.0515). This association between median income groups and WHO-FC at initial evaluation was significant (χ(2) test: P < 0.0168). There were 116 PAH patients (32 [27.6%] male, 84 [72.4%] female). There was again a negative relationship between income and initial FC (Spearman correlation: r = -0.0307, P < 0.0007). A lower SES was associated with worse disease, as measured by WHO-FC.

Entities:  

Keywords:  access to health care; disease severity; pulmonary arterial hypertension; pulmonary hypertension; right heart catheterization; socioeconomic status

Year:  2016        PMID: 27252845      PMCID: PMC4869923          DOI: 10.1086/686489

Source DB:  PubMed          Journal:  Pulm Circ        ISSN: 2045-8932            Impact factor:   3.017


  25 in total

Review 1.  Socioeconomic status and chronic obstructive pulmonary disease.

Authors:  E Prescott; J Vestbo
Journal:  Thorax       Date:  1999-08       Impact factor: 9.139

Review 2.  Primary pulmonary hypertension.

Authors:  L J Rubin
Journal:  N Engl J Med       Date:  1997-01-09       Impact factor: 91.245

3.  The effect of socioeconomic status on access to primary care: an audit study.

Authors:  Michelle E Olah; Gregory Gaisano; Stephen W Hwang
Journal:  CMAJ       Date:  2013-02-25       Impact factor: 8.262

4.  Has the 6-min walk distance run its course?

Authors:  Vallerie V McLaughlin
Journal:  Chest       Date:  2012-12       Impact factor: 9.410

5.  Effects of socioeconomic status on access to invasive cardiac procedures and on mortality after acute myocardial infarction.

Authors:  D A Alter; C D Naylor; P Austin; J V Tu
Journal:  N Engl J Med       Date:  1999-10-28       Impact factor: 91.245

6.  Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL).

Authors:  Raymond L Benza; Dave P Miller; Mardi Gomberg-Maitland; Robert P Frantz; Aimee J Foreman; Christopher S Coffey; Adaani Frost; Robyn J Barst; David B Badesch; C Gregory Elliott; Theodore G Liou; Michael D McGoon
Journal:  Circulation       Date:  2010-06-28       Impact factor: 29.690

Review 7.  Socioeconomic status and cardiovascular disease: risks and implications for care.

Authors:  Alexander M Clark; Marie DesMeules; Wei Luo; Amanda S Duncan; Andy Wielgosz
Journal:  Nat Rev Cardiol       Date:  2009-09-22       Impact factor: 32.419

8.  Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry.

Authors:  David B Badesch; Gary E Raskob; C Greg Elliott; Abby M Krichman; Harrison W Farber; Adaani E Frost; Robyn J Barst; Raymond L Benza; Theodore G Liou; Michelle Turner; Scott Giles; Kathy Feldkircher; Dave P Miller; Michael D McGoon
Journal:  Chest       Date:  2009-10-16       Impact factor: 9.410

9.  Race, socioeconomic status and stage at diagnosis for five common malignancies.

Authors:  Kendra L Schwartz; Heather Crossley-May; Fawn D Vigneau; Karl Brown; Mousumi Banerjee
Journal:  Cancer Causes Control       Date:  2003-10       Impact factor: 2.506

10.  Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial.

Authors:  N Galiè; Lj Rubin; Mm Hoeper; P Jansa; H Al-Hiti; Gmb Meyer; E Chiossi; A Kusic-Pajic; G Simonneau
Journal:  Lancet       Date:  2008-06-21       Impact factor: 79.321

View more
  9 in total

1.  Pulmonary arterial hypertension in the elderly: Clinical perspectives.

Authors:  Nicholas Rothbard; Abhinav Agrawal; Conrad Fischer; Arunabh Talwar; Sonu Sahni
Journal:  Cardiol J       Date:  2018-08-29       Impact factor: 2.737

2.  Social determinants of health in pulmonary arterial hypertension patients in the United States: Clinician perspective and health policy implications.

Authors:  Vijay R Nadipelli; Jean M Elwing; Willie H Oglesby; Karim El-Kersh
Journal:  Pulm Circ       Date:  2022-07-01       Impact factor: 2.886

Review 3.  Health Disparities in Patients with Pulmonary Arterial Hypertension: A Blueprint for Action. An Official American Thoracic Society Statement.

Authors:  Arunabh Talwar; Joe G N Garcia; Halley Tsai; Matthew Moreno; Tim Lahm; Roham T Zamanian; Roberto Machado; Steven M Kawut; Mona Selej; Stephen Mathai; Laura Hoyt D'Anna; Sonu Sahni; Erik J Rodriquez; Richard Channick; Karen Fagan; Michael Gray; Jessica Armstrong; Josanna Rodriguez Lopez; Vinicio de Jesus Perez
Journal:  Am J Respir Crit Care Med       Date:  2017-10-15       Impact factor: 21.405

4.  Impact of patient characteristics and perceived barriers on referral to exercise rehabilitation among patients with pulmonary hypertension in the United States.

Authors:  Thomas M Cascino; Carmel Ashur; Caroline R Richardson; Elizabeth A Jackson; Vallerie V McLaughlin
Journal:  Pulm Circ       Date:  2020-12-08       Impact factor: 3.017

5.  Social deprivation in Scottish populations with pulmonary hypertension secondary to connective tissue disease and chronic thromboembolic disease.

Authors:  Michael McGettrick; Paul McCaughey; Alexander MacLellan; Melanie Brewis; A Colin Church; Martin K Johnson
Journal:  ERJ Open Res       Date:  2020-11-10

6.  Socioeconomic status and survival in patients with pulmonary hypertension.

Authors:  Mei-Sing Ong
Journal:  ERJ Open Res       Date:  2020-11-10

7.  Association between income and likelihood of right heart catheterization in individuals with pulmonary hypertension: A US claims database analysis.

Authors:  Erin M Schikowski; Gretchen Swabe; Stephen Y Chan; Jared W Magnani
Journal:  Pulm Circ       Date:  2022-07-01       Impact factor: 2.886

8.  Impact of the COVID-19 and Socioeconomic Status on Access to Care for Otorhinolaryngology Patients.

Authors:  Minju Kim; Jin-A Park; Hyunkyung Cha; Woo Hyun Lee; Seung-No Hong; Dae Woo Kim
Journal:  Int J Environ Res Public Health       Date:  2022-09-20       Impact factor: 4.614

9.  Health disparities and treatment approaches in portopulmonary hypertension and idiopathic pulmonary arterial hypertension: an analysis of the Pulmonary Hypertension Association Registry.

Authors:  Hilary M DuBrock; Charles D Burger; Sonja D Bartolome; Jeremy P Feldman; D Dunbar Ivy; Erika B Rosenzweig; Jeffrey S Sager; Kenneth W Presberg; Stephen C Mathai; Matthew R Lammi; James R Klinger; Michael Eggert; Teresa De Marco; Jean M Elwing; David Badesch; Todd M Bull; Linda M Cadaret; Gautam Ramani; Thenappan Thenappan; H James Ford; Nadine Al-Naamani; Marc A Simon; Sula Mazimba; James R Runo; Murali Chakinala; Evelyn M Horn; John J Ryan; Robert P Frantz; Michael J Krowka
Journal:  Pulm Circ       Date:  2021-05-17       Impact factor: 3.017

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.